BC
MRNS

Boxer Capital’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Boxer Capital’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,400,000
Closed -$27.3M – 91
2021
Q3 		$27.3M Hold
2,400,000
– – 0.95% 30
2021
Q2 		$43.1M Hold
2,400,000
– – 1.52% 15
2021
Q1 		$37.2M Hold
2,400,000
– – 1.26% 25
2020
Q4 		$29.3M Hold
2,400,000
– – 0.94% 30
2020
Q3 		$30.8M Hold
2,400,000
– – 1.07% 26
2020
Q2 		$24.4M Buy
2,400,000
+1,200,000
+100% +$11M 1.07% 31
2020
Q1 		$9.74M Hold
1,200,000
– – 0.66% 37
2019
Q4 		$10.4M Buy
+1,200,000
New +$6.73M 0.59% 39

Other funds holding MRNS

LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Boxer Capital's MRNS Position: Q4 2021 in Review

Boxer Capital sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2021, closing a stake of 2,400,000 shares — an estimated $27.3M sold.

Boxer Capital first reported a position in MRNS in Q4 2019 and held it in 8 quarters. The position peaked at $43.1M in Q2 2021. 75 funds tracked by Wall St. Rank hold MRNS as of Q4 2021.

  • Boxer Capital reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2021 after selling out during the quarter.
  • Boxer Capital sold 2,400,000 Marinus Pharmaceuticals, Inc shares in Q4 2021, an estimated $27.3M.
  • Boxer Capital first reported a position in Marinus Pharmaceuticals, Inc in Q4 2019 and held it in 8 quarters.
  • Boxer Capital's Marinus Pharmaceuticals, Inc position peaked at $43.1M in Q2 2021.
  • 75 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2021.

Based on Boxer Capital's 13F filing for Q4 2021, filed 14 Feb 2022.